Journal Article Review Ppublish 33 citations
PubMed: 38205560 DOI: 10.37201/req/147.2023
Respiratory syncytial virus: A new era.
Rev Esp Quimioter 37(2):134-148
Authors: J Ruiz-Galiana, R Cantón, P De Lucas Ramos, A García-Botella, A García-Lledó, T Hernández-Sampelayo, J Gómez-Pavón, J González Del Castillo, M C Martín-Delgado, F J Martín Sánchez, M Martínez-Sellés, J M Molero García, S Moreno Guillén, F J Rodríguez-Artalejo, R Rodríguez Fernandez, M Kestler, E Bouza
Affiliations
- Servicio de Microbiología Clínica y Enfermedades Infecciosas del Hospital General Universitario Gregorio Marañón, Universidad Complutense. CIBERES. Ciber de Enfermedades Respiratorias. Madrid, Spain.
Abstract
Respiratory syncytial virus (RSV) is a major public health problem that has undergone significant changes in recent years. First of all, it has become easier to diagnose with highly reliable and rapidly available confirmatory tests. This has led to a better understanding of its epidemiology and RSV has gone from being a disease of the pediatric age group, severe only in infants and immunosuppressed children, to being a common disease in people of all ages, particularly important in patients of advanced age or with immunosuppressive diseases. Recent therapeutic and prophylactic advances, both with long-lasting monoclonal antibodies and vaccines, are another reason for satisfaction. For these reasons, the COVID and Emerging Pathogens Committee of the Illustrious Official College of Physicians of Madrid (ICOMEM) has considered it pertinent to review this subject in the light of new knowledge and new resources for dealing with this infection. We have formulated a series of questions that we believe will be of interest not only to members of the College but also to any non-expert in this subject, with a particular focus on the situation of RSV infection in Spain.
MeSH
Respiratory Syncytial Viruses, Drug Therapy, Viruses, Infections
Cited by
- Burden of Respiratory Syncytial Virus Infection in Children and Older Patients Hospitalized with Asthma: A Seven-Year Longitudinal Population-Based Study in Spain. Viruses, 2024
- Respiratory syncytial virus (RSV) infections in adults: Current trends and recommendations for prevention - a global challenge from a local perspective. Hum Vaccin Immunother, 2025
- A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus. Pulm Ther, 2025
- Respiratory syncytial virus: A review of current basic and clinical knowledge. Qatar Med J, 2025
- Single-Dose Intranasal Immunization with ChAd68-Vectored Prefusion F Vaccines Confers Sustained Protection Against Respiratory Syncytial Virus in Murine Models. Vaccines (Basel), 2025
- Genetic Diversity in the Fusion Gene of Respiratory Syncytial Virus (RSV) Isolated From Iraqi Patients: A First Report. Adv Virol, 2025